ES014: Clinical-Stage First-in-Class Anti-CD39xTGF-β BsAb
ES014 is a first-in-class anti-CD39xTGF-β bispecific antibody (bsAb) that simultaneously targets the adenosine and TGF-β pathways, two major immunosuppressive mechanisms in the tumor microenvironment (TME).
By simultaneously targeting CD39 and TGF-β, ES014 can inhibit the production of immunosuppressive adenosine, promote the formation of immunostimulatory ATP, and neutralize immunosuppressive cytokine TGF-β.
It works by selectively delivering TGFβ “trap” to CD39-expressing immune cells, blocking CD39-mediated adenosine production, and removing TGFβ-driven immune suppression to restore anti-tumor immunity.
Mechanism of Action
